LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

Search

MiNK Therapeutics

Gesloten

11.36 -1.47

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.12

Max

11.67

Belangrijke statistieken

By Trading Economics

Inkomsten

1.4M

-2.9M

EPS

-0.65

Winstmarge

-0.065

Werknemers

23

EBITDA

1.3M

-2.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+198.89% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.1M

57M

Vorige openingsprijs

12.83

Vorige sluitingsprijs

11.36

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

MiNK Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 dec 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec 2025, 23:51 UTC

Winsten

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dec 2025, 23:39 UTC

Belangrijke Marktbewegers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dec 2025, 21:40 UTC

Winsten

Nike Sales Tick Up, But China Weakness Persists

18 dec 2025, 23:45 UTC

Marktinformatie

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dec 2025, 23:37 UTC

Marktinformatie
Winsten

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dec 2025, 23:02 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dec 2025, 22:58 UTC

Acquisities, Fusies, Overnames

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dec 2025, 22:57 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dec 2025, 22:56 UTC

Acquisities, Fusies, Overnames

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dec 2025, 22:55 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:59 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 dec 2025, 21:35 UTC

Winsten

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dec 2025, 21:31 UTC

Winsten

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev Down 17% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q EPS 53c >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Apparel Rev $3.91B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Equipment Rev $550M >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q N Amer Rev $5.63B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Footwear Rev $7.66B >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dec 2025, 21:15 UTC

Winsten

Nike 2Q Greater China Rev $1.42B >NKE

Peer Vergelijking

Prijswijziging

MiNK Therapeutics Prognose

Koersdoel

By TipRanks

198.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35 USD  198.89%

Hoogste 35 USD

Laagste 35 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor MiNK Therapeutics - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

7.81 / 8.1Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

help-icon Live chat